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Abstract
Background The Dutch Pediatric Formulary (DPF) increasingly bases its guidelines on model-based dosing simulations from 
pharmacokinetic studies. This resulted in nationwide dose changes for vancomycin, gentamicin, and tobramycin in 2015.
Objective We aimed to evaluate target attainment of these altered, model-based doses in critically ill neonates and children.
Methods This was a retrospective cohort study in neonatal intensive care unit (NICU) and pediatric ICU (PICU) patients 
receiving vancomycin, gentamicin, or tobramycin between January 2015 and March 2017 in two university hospitals. The 
first therapeutic drug monitoring concentration for each patient was collected, as was clinical and dosing information. Van-
comycin and tobramycin target trough concentrations were 10–15 and ≤ 1 mg/L, respectively. Target gentamicin trough and 
peak concentrations were < 1 and 8–12 mg/L, respectively.
Results In total, 482 patients were included (vancomycin [PICU] n = 62, [NICU] n = 102; gentamicin [NICU] n = 97; 
tobramycin [NICU] n = 221). Overall, median trough concentrations were within the target range for all cohorts but showed 
large interindividual variability, causing nontarget attainment. Trough concentrations were outside the target range in 66.1%, 
60.8%, 14.7%, and 23.1% of patients in these four cohorts, respectively. Gentamicin peak concentrations were outside the 
range in 69% of NICU patients (term neonates 87.1%, preterm infants 57.1%). Higher creatinine concentrations were associ-
ated with higher vancomycin and tobramycin trough concentrations.
Conclusion This study illustrates the need to validate model-based dosing advice in the real-world setting as both sub- and 
supratherapeutic concentrations of vancomycin, gentamicin, and tobramycin were very prevalent. Our data underline the 
necessity for further individualization by addressing the high interindividual variability to improve target attainment.
A comment on this article is available at https ://doi.org/10.1007/
s4027 2-020-00402 -6.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 2-020-00400 -8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
The Dutch Pediatric Formulary (DPF) is a national, best-
evidence drug formulary that provides monographs for over 
750 different drugs used in children [1]. It aims to unify 
prescribing for children by providing best-evidence dosing 
recommendations. Over time, drug monographs in the DPF 
are regularly updated as new, relevant information becomes 
available in the literature.
Recently, multiple vancomycin, gentamicin, and tobramy-
cin population pharmacokinetic studies have been performed 
in neonates and children [2–4]. These studies showed that 
standard doses of these antibiotics frequently led to subther-
apeutic exposure in specific pediatric subgroups. Therefore, 
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Key Points 
In 2015, age- and weight-based dosing guidelines in 
the Dutch Pediatric Formulary were updated for vanco-
mycin, gentamicin, and tobramycin based on published 
population pharmacokinetic studies. Target attainment 
resulting from these model-based doses was unknown.
This study shows that both sub- and supratherapeutic 
concentrations of vancomycin, gentamicin, and tobramy-
cin are frequently observed, with serum creatinine levels 
related to the observed variability.
Future dosing recommendations should aim to be fur-
ther individualized by including relevant covariates to 
address the remaining interindividual variability.
therapeutic drug monitoring (TDM) data in two sites to 
assess target attainment.
We conducted a retrospective, two-center cohort study 
among patients admitted to the level 3 neonatal intensive 
care units (NICUs) or PICUs of either Erasmus MC’s Sophia 
Children’s Hospital or Radboudumc’s Amalia Children’s 
Hospital after the dosing guidelines were altered in 2015 
and up to March 2017. The Medical Ethics Review Commit-
tee of the Erasmus MC reviewed the research proposal and 
waived the need for formal approval of the study protocol 
according to the Dutch Law on Human Research. The obli-
gation for individual informed consent was waived because 
of the retrospective nature of this study.
The advised dose and/or dose interval of vancomycin, 
tobramycin, and gentamicin were altered and posted on the 
DPF’s open access internet platform (https ://www.kinde 
rform ulari um.nl) on 23 January, 23 October, and 23 June 
2015, respectively, as shown in Table 1. The formulary pro-
vides guidance for dose adjustment in case of renal dys-
function for children aged > 1 month but not for younger 
children.
2.2  Inclusion and Exclusion Criteria
The electronic database of hospital admissions of both hos-
pitals was screened for records of potential patients. All 
patients admitted to the NICU or PICU and who received 
at least one dose of vancomycin, gentamicin, or tobramycin 
were included in this initial screening.
Inclusion criteria were as follows: postnatal age 
(PNA) < 18 years; admitted to the NICU or PICU; treated 
with intravenous vancomycin, gentamicin, or tobramycin 
during ICU admission; and having at least one (steady-state) 
trough concentration or peak concentration determined as 
part of TDM.
Patients were excluded if they (1) received a dose that 
was not concordant with the post-2015 DPF guidelines 
(which was defined as a daily drug dose and dose interval 
that deviated > 10% from the post-2015 dosing advice shown 
in Table 1), (2) received oral or enteral therapy, (3) started 
treatment before being admitted to the ICU, (4) required 
extracorporeal membrane oxygenation or hemofiltration 
therapy during antibiotic treatment, (5) were aged > 18 years 
PNA, or (6) had no accurate (steady-state) trough or peak 
concentration determined as part of TDM. This sixth exclu-
sion criterion could mean patients in which no TDM sam-
ple was available at all, for example with transient clinical 
symptoms of infection or postsurgical antibiotic prophylaxis 
for which antibiotic therapy was discontinued before the first 
TDM sample was planned or if a vancomycin concentration 
was measured before steady state had been achieved. Steady 
state of vancomycin was defined as at least three half-lives 
between treatment start and blood sample, with the half-life 
the DPF updated its dosing advice for subgroups of neonates 
and children for these antibiotics in 2015.
One of the challenges with adapting dosing recommen-
dations based on simulations using population pharmacoki-
netic models is the external validity of the guidelines. Patient 
selection may be biased, as certain age groups may be under-
represented, patients with certain levels of organ failure 
may have been excluded (e.g., renal failure), or units may 
be focused on specific disease states (e.g., pediatric inten-
sive care unit [PICU] with a large proportion of post cardiac 
surgery patients). These patient and unit details are often not 
described in detail in the manuscripts. Hence, while we felt 
that the published model-based dosing recommendations for 
vancomycin, gentamicin, and tobramycin were adequately 
validated, there was a need for a pragmatic study to assess 
the adequacy of target attainment for these antibiotics in a 
real-life setting to ensure the changed dosing recommenda-
tions were effective and safe.
With this pilot study, we aimed to externally validate the 
adjusted, model-based DPF dosing guidelines for vancomy-
cin, gentamicin, and tobramycin in critically ill neonates and 
children. Additionally, we explored risk factors for sub- or 
supratherapeutic concentrations to provide a basis for further 
optimization of pediatric dosing guidelines.
2  Methods
2.1  Study Design
A prospective two-center study to validate the population 
pharmacokinetic models and the resulting dosing recom-
mendations was outside of the DPF’s available resources, 
so we took a more pragmatic approach to use retrospective 
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in preterms < 7 days of PNA, preterms ≥ 7 days PNA, term 
neonates, and PICU patients estimated at 12, 8, 6, and 6 h, 
respectively [5, 6].
Per patient, we included only the first steady-state trough 
concentration for vancomycin and the first trough and peak 
concentration of gentamicin and tobramycin, before TDM 
alterations in dose or dose interval had occurred, as con-
centrations determined after TDM would not reflect the tar-
get attainment of the current dose advice. We chose not to 
exclude patients for whom the dose advice was not altered 
in 2015, e.g., preterm neonates treated with vancomycin, to 
truly reflect target attainment and safety of these drugs in 
current clinical practice.
2.3  Data Collection
Clinical data were retrospectively collected from electronic 
health records at both hospitals from 1 January 2015 up 
to 1 March 2017. Collected data were basic demographic 
characteristics, admission data, antibiotic doses and their 
respective date and time of administration, antibiotic plasma 
levels and their respective date and time of determination, 
and serum creatinine concentrations. For neonates, gesta-
tional age (GA) at birth and birth weight were collected. 
Results of validated pediatric disease severity scores 
(Pediatric Index of Mortality [PIM]-II, Pediatric Logistic 
Organ Dysfunction [PELOD], Pediatric Risk of Mortality 
[PRISM]-III scores within 24 h after ICU admission) were 
obtained for PICU patients only, as these disease severity 
scores are not validated for neonates.
Drug concentrations were analyzed using a particle-
enhanced turbidimetric inhibition immunoassay (Architect, 
Abbott Laboratories, Lake Bluff, IL, USA) for gentamicin, 
tobramycin, and vancomycin in the Erasmus MC. This 
assay has lower and upper limits of quantification of 0.2 
and 40 mg/L for gentamicin and tobramycin, and 1.1 and 
40 mg/L for vancomycin, respectively. In the Radboudumc, 
plasma concentrations were analyzed using a commercially 
Table 1  Overview of dose advice for vancomycin, gentamicin, and tobramycin in the Dutch Pediatric Formulary before and after the model-
based dose alterations in 2015
Daily dose and dose interval before and after the dose change of 2015 for vancomycin, gentamicin, and tobramycin. Dose advice is presented for 
different subgroups based on PNA and GA. Patients with a GA ≥ 37 weeks are categorized as “term” and patients with GA < 37 weeks as “pre-
term” if no specific GA range is specified
GA gestational age at birth, PNA postnatal age
a Change in the recommended daily dose or dose interval after 2015
Drug and subgroup Before 2015 After 2015
Daily dose Dose interval (h) Daily dose Dose 
interval 
(h)
Vancomycin
 Preterm, < 7 days PNA 20 mg/kg/day 12 20 mg/kg/day 12
 Preterm, ≥ 7 days PNA 30 mg/kg/day 8 30 mg/kg/day 8
 Term, < 7 days PNA 20 mg/kg/day 12 32 mg/kg/daya 6a
 Term, ≥ 7 days PNA 30 mg/kg/day 8 48 mg/kg/daya 6a
 1 month–18 years 40 mg/kg/day 8 60 mg/kg/daya 6a
Gentamicin
 Preterm < 32 weeks GA, < 7 days  PNA 4 mg/kg/dose 48 5 mg/kg/dosea 48
 Preterm 32–37 weeks GA, < 7 days PNA 4 mg/kg/dose 36 5 mg/kg/dosea 36
 Preterm, ≥ 7 days PNA 4 mg/kg/dose 36–48 4 mg/kg/dose 24a
 Term, < 7 days PNA 4 mg/kg/dose 24 4 mg/kg/dose 24
 Term, ≥ 7 days PNA 4 mg/kg/dose 24 4 mg/kg/dose 24
 1 month–18 years 7 mg/kg/dose 24 7 mg/kg/dose 24
Tobramycin
 Preterm < 32 weeks GA, < 7 days PNA 4 mg/kg/dose 48 4 mg/kg/dose 48
 Preterm 32–37 weeks GA, < 7 days PNA 4 mg/kg/dose 36 4 mg/kg/dose 36
 Preterm, ≥ 7 days PNA 4 mg/kg/dose 36–48 4 mg/kg/dose 24a
 Term, < 7 days PNA 4 mg/kg/dose 24 4 mg/kg/dose 24
 Term, ≥ 7 days PNA 4 mg/kg/dose 24 4 mg/kg/dose 24
 1 month–18 years 5–7 mg/kg/dose 24 5–7 mg/kg/dose 24
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available, validated immunoassay (Cobas, Roche Diagnos-
tics GmbH, Mannheim, Germany) with lower and upper lim-
its of quantification of 0.4 and 10 mg/L, 0.33 and 10 mg/L, 
and 4.0 and 80 mg/L for gentamicin, tobramycin, and van-
comycin, respectively.
Data cleaning was carried out in accordance with the 
methods proposed by Van den Broeck et al. [7], and missing 
variables as well as possible outliers were double checked in 
the hospitals’ patient databases.
2.4  Statistical Analysis
Four cohorts were established based on the administered 
antibiotic and ICU type: vancomycin NICU, vancomycin 
PICU, gentamicin NICU, and tobramycin NICU. Patients in 
the vancomycin and gentamicin cohorts were divided into 
three subgroups (subtherapeutic, therapeutic, and suprather-
apeutic), whereas patients in the gentamicin and tobramycin 
cohorts were divided into two subgroups (safe and toxic), 
according to the pharmacodynamic target concentrations 
for efficacy and/or safety. Therapeutic pharmacodynamic 
targets for drug efficacy were considered as a vancomycin 
trough concentration of 10–15 mg/L (as a surrogate marker 
for the adult pharmacodynamic target of area under the 
plasma concentration–time curve [AUC]/minimum inhibi-
tory concentration [MIC] ratio > 400) [8, 9] and gentamicin 
peak concentration of 8–12 mg/L [10]. Tobramycin peak 
concentrations are not routinely performed during TDM, 
so a pharmacodynamic target for tobramycin efficacy 
was not addressed. Additionally, target trough concentra-
tions for vancomycin, gentamicin, and tobramycin safety 
were > 15 mg/L and ≤ 1.0 mg/L for both aminoglycoside 
drugs, respectively [10, 11].
Descriptive data are presented as medians and interquar-
tile ranges (IQRs), and categorical data are presented as 
whole numbers and percentages. Attainment of the afore-
mentioned pharmacodynamic targets for efficacy and safety 
is presented as the percentage of patients within the entire 
cohort and in each of the dosing subgroups outlined in 
Table 1.
Correlations between antibiotic trough concentrations and 
potential covariates (creatinine, disease severity scores) were 
assessed with Spearman’s rank correlation using GraphPad 
version 5.03. Serum creatinine concentrations within 24 h 
of TDM were used as a covariate for glomerular filtration 
rate (GFR), as vancomycin, gentamicin, and tobramycin 
are all predominantly excreted by glomerular filtration. 
Subsequently, we tested the correlation of creatinine con-
centrations within 24 h of the start of treatment to inves-
tigate whether creatinine could guide antibiotic dosing at 
treatment commencement. Additionally, in the vancomycin 
PICU cohort, we tested several validated pediatric disease 
severity scores (PIM-II, PELOD, PRISM-III scores) to 
assess the correlation of critical illness with vancomycin 
trough concentrations [12–14].
3  Results
3.1  Patient Characteristics
In total, 1642 patients who were screened as admitted to the 
NICU or PICU in either of the hospitals between January 
2015 and March 2017 and received vancomycin, gentamicin, 
or tobramycin during their ICU admission. Of these, 1160 
were excluded, mainly because no (steady-state) peak or 
trough concentration was available (n = 923, mainly in 
the gentamicin and tobramycin cohorts) or because they 
received a dose not in concordance with the new dosing 
guidelines for patients with normal renal function, leaving 
482 patients for data analysis (Fig. 1). An overview of the 
clinical characteristics of each cohort is shown in Table 2. 
3.2  Target Attainment
The percentage of target attainment, arranged by drug, unit, 
and age group, is presented in Table 3, with a visual repre-
sentation in Fig. 2a–d. All cohorts and subgroups showed 
significant interindividual variation, even though all patients 
within a subgroup received a similar daily dose and dose 
interval. Interindividual variation seems similar between 
subgroups whose dose was altered in 2015, represented by 
triangles in Fig. 2, compared with subgroups for which no 
dose alteration was recommended. 
3.2.1  Vancomycin PICU cohort
In total, 62 patients were included in the vancomycin 
PICU cohort, with a median age of 0.8 years, ranging 
from 33 days to 17.1 years (Table 2). Median vancomycin 
trough concentrations (12.5 mg/L) were within the target 
range but showed great interindividual variation, ranging 
from 3.3 to 47.9 mg/L (Fig. 2a). Therapeutic trough con-
centrations showed a prevalence of 33.9%, with 30.6 and 
35.5% of patients having subtherapeutic and suprathera-
peutic concentrations, respectively (Fig. 2a, Table 3).
3.2.2  Vancomycin NICU Cohort
In total, 102 patients were included in the vancomycin 
NICU cohort, with the majority (70.6%) being preterm 
infants (GA < 32 weeks) (Table 2). Overall, the median 
trough concentration was 12.6 mg/L (range 3.2–55.6 [IQR 
8.6–16.9]), with 39.2, 28.4, and 32.4% of patients having 
therapeutic, subtherapeutic, and supratherapeutic trough 
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concentrations, respectively (Fig.  2b, Table  3). Term 
neonates aged > 1 week showed the worst target attain-
ment of only 10%, with 90% of supratherapeutic trough 
concentrations > 15 mg/L (Table 3). In a subgroup of 36 
extremely preterm neonates, aged ≤ 28 weeks of gestation, 
we found a similar overall proportion of nontarget attain-
ment (63.9%) compared with the subgroup of 36 preterms 
with a GA of 28–32 weeks (58.3%). Extremely premature 
neonates showed slightly more supratherapeutic drug con-
centrations (36.1 vs. 19.4% in the “older” subgroup).
3.2.3  Gentamicin NICU cohort
A total of 97 patients were included in the gentamicin NICU 
cohort, contributing 87 peak concentrations and 95 trough 
concentrations of gentamicin. Median gentamicin peak and 
trough concentrations were 7.2 and 0.8 mg/L, respectively 
(Table 3). Gentamicin peak concentrations were mostly sub-
therapeutic (67.8%) and rarely supratherapeutic (1.1%), and 
the majority of trough concentrations (85.3%) were below 
the toxicity threshold of ≤ 1.0 mg/L (Table 3). Both sub-
therapeutic peak concentrations and toxic trough levels were 
most prevalent in preterm patients ≥ 7 days (100 and 21.4%, 
respectively) and term patients (87.1% and 29.4%, respec-
tively), with both of these subgroups receiving 4 mg/kg/24 h 
as opposed to 5 mg/kg/36–48 h in preterm patients < 7 days 
PNA (Table 3, Fig. 2c).
3.2.4  Tobramycin NICU Cohort
The 221 patients in the tobramycin NICU cohort were 
mostly preterm infants (65.6%). Median tobramycin trough 
concentrations were 0.6 mg/L, with 23.1% of samples show-
ing toxic concentrations (Tables 2 and 3). Toxic tobramy-
cin trough concentrations were most prevalent in patients 
dosed every 24  h (term patients [36.8%] and preterm 
patients ≥ 7 days PNA [25.4%]) and least prevalent in pre-
term patients < 7 days of PNA who are dosed every 36–48 h 
(2.2% for < 32 weeks and 14.3% for 32–37 weeks of gesta-
tion) (Fig. 2d, Table 3). In a subgroup of 71 extreme pre-
terms, the prevalence of toxic trough concentrations (18.3%) 
was comparable to the prevalence found in 42 preterms with 
a higher GA of 28–32 weeks (14.3%).
3.3  Correlation With Covariates
As creatinine concentrations are not routinely checked dur-
ing regular care, these data were frequently missing: 16, 
48, 41, and 52% of patients had no creatinine concentra-
tion determined within 24 h of the TDM sample for the 
Fig. 1  Flowchart indicating 
the total number of patients, 
number of exclusions, reason 
for exclusion, total number of 
inclusions, and stratification 
among our four cohorts. ECMO 
extracorporeal membrane oxy-
genation, MC medical center, 
NICU neonatal intensive care 
unit, PICU pediatric intensive 
care unit
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vancomycin PICU, vancomycin NICU, gentamicin NICU, 
and tobramycin NICU cohort, respectively (Table 1).
The relationship between creatinine at the start of treat-
ment and drug concentrations at steady state was statistically 
significant for vancomycin in NICU and PICU cohorts and 
for tobramycin (Spearman’s rho 0.427, 0.441, and 0.281, 
respectively; p = 0.0011, 0.0008, and 0.0407) (Fig. 3a, b, 
and d, respectively). Creatinine concentrations on the day of 
TDM and antibiotic trough concentrations were also corre-
lated for vancomycin in both the NICU and the PICU cohort 
and for tobramycin (Spearman’s rho 0.502, 0.520, and 0.541, 
respectively; p < 0.0001) (Fig. 3e, f, and h, respectively). In 
contrast, gentamicin trough concentrations showed no statis-
tically significant correlation with creatinine concentrations 
at the start of treatment (Spearman’s rho 0.219; p = 0.102) 
or on the day of TDM (Spearman’s rho 0.200; p = 0.235) 
(Fig. 3c and g, respectively).
In the vancomycin PICU cohort, trough concentrations 
were correlated with two of the three tested disease severity 
scores. Statistically significant correlation coefficients were 
seen for the PIM-II score (Spearman’s rho 0.323; p = 0.011) 
and PELOD scores (Spearman’s rho 0.256; p = 0.047) but 
not for PRISM-III scores (Spearman’s rho 0.060; p = 0.646) 
(Fig. 1 in the electronic supplementary material, panels A, 
B, and C, respectively).
4  Discussion
In this retrospective two-center cohort study, we investigated 
the target attainment of three antibiotic agents in critically 
ill neonates and children after a nationwide model-based 
dosing guideline change. Overall, median concentrations of 
the studied drugs fell within the nontoxic, therapeutic range 
for all cohorts. However, because of the large interindividual 
variability seen in this patient population, a significant pro-
portion of patients showed supra- and subtherapeutic drug 
levels of vancomycin, gentamicin, and tobramycin. This 
Table 2  Demographic characteristics of patients in each of the four cohorts
Numbers are presented as median (IQR) [range] or n (%)
GA gestational age, ICU intensive care unit, NICU neonatal intensive care unit, PELOD Pediatric Logistic Organ Dysfunction, PICU pediatric 
intensive care unit, PIM Pediatric Index of Mortality, PNA postnatal age, PRISM Pediatric Risk of Mortality, TDM therapeutic drug monitoring
a Data not collected in this cohort
Characteristics Vancomycin PICU
(n = 62)
Vancomycin NICU
(n = 102)
Gentamicin NICU
(n = 97)
Tobramycin NICU
(n = 221)
PNA at treatment start 0.8 years (0.3–8.6) 8.0 days (6.0–13.3) 1.0 days (0.0–3.0) 3.0 days (2.0–9.0)
PNA < 7 days 0 (0) 27 (26.5) 81 (83.5) 146 (66.1)
PNA ≥ 7 days 62 (100) 75 (73.5) 16 (16.5) 75 (33.9)
GA at birth –a 29.0 weeks (27.0–34.1) 
[23.9–42.3]
31.7 weeks (28.5–38.6) 
[23.9–41.9]
31.4 weeks (27.0–38.3) 
[24.0–41.9]
 < 32 weeks –a 72 (70.6) 50 (51.5) 113 (51.1)
32–37 weeks –a 10 (9.8) 12 (12.4) 32 (14.5)
 ≥ 37 weeks –a 20 (19.6) 35 (36.1) 76 (34.4)
Weight (kg) 8.1 (5.0–30.1) 1.2 (0.9–2.1) 1.7 (1.2–3.2) 1.6 (1.0–3.1)
Male 31 (50) 61 (59.8) 53 (54.6) 138 (62.4)
ICU mortality 6 (9.7) 7 (6.9) 5 (5.2) 35 (15.8)
Duration of ICU admission 
(days)
17.5 (6.0–41.5) 19.5 (10.0–44.3) 12 (4.0–24.5) 15.6 (6.5–44.7)
PRISM-III score 15 (8–21) –a –a –a
PIM-II expected mortal-
ity (%)
1.9% (0.9–3.4) –a –a –a
PELOD score 6.0 (2.5–9), missing = 1 –a –a –a
Creatinine concentration at 
start of antibiotic treat-
ment
34.5 µmol/L (20–53), miss-
ing = 8
48 µmol/L (32–61), miss-
ing = 47
70 µmol/L (64–80), miss-
ing = 60
71 µmol/L (60–90), 
missing = 159
Creatinine concentration at 
TDM
29 µmol/L (19–52), miss-
ing = 10
39 µmol/L (32–59), miss-
ing = 49
64 µmol/L (47–71), miss-
ing = 40
65 µmol/L (49–82), 
missing = 116
Antibiotic trough concen-
tration (mg/L)
12.5 (8.8–20.7) 12.6 (8.6–17.0) 0.8 (0.6–0.8) 0.6 (0.3–1.0)
Antibiotic peak concentra-
tion
–a –a 7.2 mg/L (6.1–8.1) –a
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shows that the pharmacokinetic models used for generating 
the dose advice accurately simulated overall concentrations 
but did not fully address the sources of variability in criti-
cally ill neonates and children. Surprisingly, target attain-
ment was worst for term neonates and preterm neonates 
older than 1 week of PNA, with both groups showing the 
highest percentage of nontherapeutic peak concentrations 
and/or potentially toxic trough concentrations for all three 
drugs. Serum creatinine concentrations correlated moder-
ately well with drug concentrations at the time of dosing and 
at sampling for vancomycin and tobramycin, which could be 
used for further optimization and individualization of dosing 
recommendations.
Reduced target attainment of antibiotics is common in 
critically ill neonates and children. Other studies that used 
population, dose, dose interval, and pharmacodynamic tar-
gets relatively similar to those in our study found similar 
results for vancomycin [15, 16] and gentamicin [17]. De 
Cock et al. [15] showed an even lower target attainment of 
vancomycin in PICU patients of only 8% compared with our 
33.9%. In critically ill neonates, overall target attainment of 
vancomycin was also lower (23 vs. our 39%) in the study 
by Koedood et al. [16], with a slightly higher proportion of 
subtherapeutic concentrations (43 vs. our 28.4%). In another 
study, gentamicin peak concentrations did not reach thera-
peutic concentrations in > 50% of neonates receiving a dose 
of 4–5 mg/kg [17]. The same authors also showed a high 
proportion of trough concentrations ≥ 1.0 mg/L in neonates 
aged > 7 days who receive a single daily dose of gentamicin 
(20%) [17].
The current drug dosing guidelines of the DPF seem to 
overestimate average clearance of term neonates and preterm 
neonates aged > 1 week, as is shown by the large proportion 
of high trough concentrations of vancomycin, gentamicin, 
Table 3  Overview of efficacy and safety target attainment of vancomycin, gentamicin, and tobramycin in each cohort
Data are presented as n (%). Target attainment for vancomycin, gentamicin, and tobramycin in the four different cohorts. Therapeutic concentra-
tions were defined as a vancomycin trough concentration of 10–15 mg/L and gentamicin peak concentration of 8–12 mg/L. Safety for gentamicin 
and tobramycin was defined as trough concentrations ≤ 1  mg/L. Patients with a GA ≥ 37  weeks are categorized as “term” and patients with 
GA < 37 weeks as “preterm” if no specific GA range was specified. Boldface text represents patient subgroups for which the dose advice was 
altered in 2015. Plain text represents groups for which no alteration in dose or dose interval was made
GA gestational age, NICU neonatal intensive care unit, PICU pediatric intensive care unit, PNA postnatal age
a n deviates from number of patients in the total cohort or subgroups because of missing data of peak or trough concentrations
Efficacy Subtherapeutic Therapeutic Supratherapeutic
Vancomycin PICU (total) (n = 62) 19 (30.6) 21 (33.9) 22 (35.5)
Vancomycin NICU (total) (n = 102) 29 (28.4) 40 (39.2) 33 (32.4)
 Preterm GA +  < 7 days PNA (n = 17) 7 (41.2) 6 (35.3) 4 (23.5)
 Preterm GA +  ≥ 7 days PNA (n = 65) 20 (30.8) 28 (43.1) 17 (26.2)
 Term GA +  < 7 days PNA (n = 10) 2 (20.0) 5 (50.0) 3 (30.0)
 Term GA +  ≥ 7 days PNA (n = 10) 0 (0.0) 1 (10.0) 9 (90.0)
Gentamicin NICU (total) (n = 87)a 59 (67.8) 27 (31.0) 1 (1.1)
  < 32 weeks GA +  < 7 days PNA (n = 36)a 16 (44.4) 20 (55.6) 0 (0.0)
  < 32 weeks GA +  ≥ 7 days PNA (n = 9)a 9 (100.0) 0 (0.0) 0 (0.0)
 32–37 weeks GA +  < 7 days PNA (n = 9)a 5 (55.6) 3 (33.3) 1 (11.1)
 32–37 weeks GA +  ≥ 7 days PNA (n = 2) 2 (100.0) 0 (0.0) 0 (0.0)
 Term GA + any PNA (n = 31)a 27 (87.1) 4 (12.9) 0 (0.0)
Safety – Safe Toxic
Gentamicin NICU (total) (n = 95)a – 81 (85.3) 14 (14.7)
  < 32 weeks GA +  < 7 days PNA (n = 38) – 38 (100.0) 0 (0.0)
  < 32 weeks GA +  ≥ 7 days PNA (n = 12) – 9 (75.0) 3 (25.0)
 32–37 weeks GA +  < 7 days PNA (n = 9)a – 8 (88.9) 1/9 (11.1)
 32–37 weeks GA +  ≥ 7 days PNA (n = 2) – 2 (100.0) 0 (0.0)
 Term GA + any PNA (n = 34)a – 24 (70.6) 10 (29.4)
Tobramycin NICU (total) (n = 221) – 170 (76.9) 51 (23.1)
  < 32 weeks GA +  < 7 days PNA (n = 46) – 45 (97.8) 1 (2.2)
 32–37 weeks GA +  < 7 days PNA (n = 28) – 24 (85.7) 4 (14.3)
 Term GA + any PNA (n = 76) – 48 (63.2) 28 (36.8)
 Preterm GA +  ≥ 7 days PNA (n = 71) – 53 (74.6) 18 (25.4)
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Fig. 2  Concentrations of 
vancomycin, gentamicin, and 
tobramycin in critically ill neo-
nates and children. Overview 
of (steady-state) concentrations 
of vancomycin, gentamicin, 
and tobramycin concentrations 
in four cohorts. a Vancomycin 
NICU, b vancomycin PICU, 
c gentamicin NICU, and d 
tobramycin NICU cohorts. 
Upward facing triangles repre-
sent patient subgroups for which 
the dose advice was altered in 
2015, open circles represent 
subgroups for which no altera-
tion in dose or dose interval was 
made. Blue symbols represent a 
single-patient trough concen-
tration, red symbols represent 
gentamicin peak concentrations. 
Dashed lines indicate the target 
concentrations. NICU neonatal 
intensive care unit, PICU pedi-
atric intensive care unit
Fig. 3  Correlation of antibiotics trough concentrations with creati-
nine concentrations at start of antibiotic treatment and on the day of 
TDM. Correlation of antibiotic trough concentrations with creatinine 
concentrations taken within 24 h of start of antibiotic treatment (a–d) 
or within 24 h of the TDM sample (e–h). Open circles represent sin-
gle-patient creatinine and antibiotic trough concentrations. The solid 
line represents the linear regression line. Correlation coefficients, 
p values, and number of patients are presented in each panel in the 
corresponding legend box. Number of patients may deviate from 
total patient cohort because of missing creatinine data. n number of 
patients, NICU neonatal intensive care unit, PICU pediatric intensive 
care unit, rho Spearman’s rho correlation coefficient, TDM therapeu-
tic drug monitoring
External Validation of Model-Based Dosing Guidelines in Critically Ill Neonates and Children
and tobramycin in this study. The cause of this overestima-
tion might lie in the studied populations on which the dose 
changes were based. De Cock et al. [15] used pharmacoki-
netic data for vancomycin, gentamicin, and tobramycin from 
four different studies [18–21], all including NICU and PICU 
patients with and without renal dysfunction but excluding 
patients with severe renal dysfunction. The aim of this study 
was to identify the impact of developmental changes of GFR 
on the clearance of gentamicin, tobramycin, and vancomy-
cin. In total, over 4000 blood samples from 1760 unique 
patients were used to generate a semi-physiological phar-
macokinetic model of this impact. The majority of patients 
in this study were neonates aged < 1 month (1428 patients, 
81%), with a gestational age ranging from 23 to 43 weeks. 
In total, 180, 95, and 57 patients aged 1 month–2 years, 
2–11 years, and 12–18 years, respectively, completed the 
study cohort. Their model describes the maturation in GFR 
from neonates to adults using a bodyweight-dependent expo-
nent that is similar for all three studied drugs and can be 
used for subsequent pharmacokinetic modeling and simula-
tion studies. Subsequent studies by Janssen et al. [3] and 
Valitalo et al. [4] aimed to validate these findings and to 
generate model-based dosing advice for the whole pediatric 
age range but in their external validation did not use a “new” 
external dataset [4] and/or performed drug exposure simula-
tions only for patients with normal renal function [3, 4]. As 
this dosing advice is applied nationwide, and for critically 
ill neonates and children with highly varying renal function, 
this creates a discrepancy between the modeled population 
and the actual population.
Additionally, our data on gentamicin peak concentra-
tions suggested that the majority of concentrations were 
subtherapeutic, with term neonates and preterm neonates 
aged ≥ 7 days showing the lowest target attainment. This 
could be because Valitalo et  al. [4] modeled for target 
peak concentrations of 5–12 mg/L, whereas we defined a 
target peak concentration of 8–12 mg/L based on current 
national guidelines [10]. This higher target concentration 
in our study was based on literature of the pharmacody-
namic targets for aminoglycoside antibiotics, wherefor the 
maximum effectiveness of the drug is reached when peak 
concentrations are six to eight times higher than the MIC of 
the micro-organism. This discrepancy shows another chal-
lenge when extrapolating dosing recommendations. Not only 
may patient characteristics differ but pharmacodynamic end-
points are also a factor for consideration.
The most prevalent Gram-negative pathogen in early-
onset neonatal sepsis is Escherichia coli [22], which has 
MICs of 1–2 mg/L according to the EUCAST database 
[23]. Hence, peak concentrations of gentamicin of at least 
8–12 mg/L are needed to acquire the desired exposure. 
Whether these higher target concentrations as proposed in 
the new Dutch treatment guideline are warranted for every 
patient is debatable, as these pharmacodynamic targets are 
mostly defined in vitro, in animal or adult studies and might 
not apply to the NICU setting, where empirical treatment 
and combination therapy of broad-spectrum antibiotics is 
more prevalent [24].
The observed wide interindividual variability in antibiotic 
plasma concentrations in patients using the same weight-
corrected dose is a common finding among studies in criti-
cally ill children and neonates [18, 25]. This study shows 
that a linear dose alteration (e.g., vancomycin in children 
aged > 1 month increased from 40 to 60 mg/kg/day) does 
not address this issue, as it only increases average plasma 
concentrations but does not account for interindividual vari-
ability because of factors other than weight, such as renal 
function.
Renal dysfunction is acknowledged as an important 
factor warranting vancomycin and aminoglycoside dose 
adjustment. The DPF provides dosing guidance for chil-
dren aged > 1 month with renal dysfunction, although these 
patients were not included in our current analyses. How-
ever, because such guidance is lacking for younger children, 
neonates with renal dysfunction may have received regular 
drug doses. This may have contributed to the overestima-
tion in clearance in a substantial proportion of neonates 
aged > 7 days. Interestingly, even in patients without renal 
dysfunction, serum creatinine correlates with drug concen-
trations of vancomycin [16, 26–33], gentamicin [19, 34], 
and tobramycin [35–37]. This warrants possibly also using 
creatinine concentrations to aid personalized dosing strate-
gies for patients with normal or augmented renal clearance.
Our study has some limitations. First, it is a retrospec-
tive study using clinical data that were not specifically 
collected for research properties, which resulted in a rela-
tively high percentage of missing data, for example for 
serum creatinine concentrations or detailed information 
on the current disease state of patients (e.g., septic shock) 
or comedication. Furthermore, this retrospective design 
could have introduced a selection bias, as only NICU and 
PICU patients who had their antibiotic concentrations 
measured during their ICU stay were included. Therefore, 
target attainment in patients treated for different indica-
tions or with less severe clinical symptoms might differ 
from our results. Additionally, some subgroups are rel-
atively underrepresented in our study, such as neonates 
aged ≥ 7 days within the GA groups of 32–37 weeks and 
term (n = 2 for both groups) in the gentamicin cohort. This 
indicates that results in another setting (e.g., other patient 
populations, medium care wards, or other hospitals) could 
differ from ours. Lastly, we investigated a selection of pos-
sible covariates (serum creatinine, age, and PICU disease 
severity scores), but other factors could also influence 
drug levels, including fluid balance or the use of nephro-
toxic and/or vasopressor comedication. These additional 
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covariates could also be a significant source of variability 
that will need to be addressed in future research.
As mentioned, the intra- and interpatient variability seen 
in critically ill neonates and children is large and is one of 
the main factors that contribute to the difficulty of dosing 
this heterogeneous group of patients. In recent years, phar-
macokinetic modeling has become one of the main means 
to identify the sources of this variability in various special 
population subgroups that show differences in pharmacoki-
netic parameters (such as neonates/children, the critically ill, 
and patients with sepsis, obesity, or cancer). To date, phar-
macokinetic models have mainly focused on addressing the 
impact of age and body size on drug disposition. Our data 
now suggest that the interplay with other factors, such as 
renal function and other clinical covariates, appears impor-
tant to optimize dosing in (critically ill) children. Although 
future research should expand on this identification of rele-
vant covariates on pharmacokinetics, it should also focus on 
the implementation and external validation of these models 
in daily clinical practice. In a 2015 Delphi study, a reporting 
guideline for pharmacokinetic studies, outlined the mini-
mally included information in pharmacokinetic studies [38]. 
This included information in the literature, basic pharma-
cokinetic parameter findings, and sources of inter- and intra-
patient variability. Although this guideline provides a good 
basis for high-quality reporting of pharmacokinetic studies, 
formularies such as the DPF can be aided further in the clini-
cal implementation and external validation of these findings 
by providing the following additional elements in pharma-
cokinetic research articles: (1) a detailed overview of the 
studied population (including age, underlying pathologies, 
inclusion or exclusion of patients with renal or liver dysfunc-
tion); (2) information on the pharmacodynamic targets used 
for the evaluation of efficacy and toxicity, with (for antibi-
otics) information on the prevalence of MIC distributions 
that were used and a rationale for this target range; and (3) 
substantiated dose advice or simulations of different doses. 
Preferably, this would include an overview of the propor-
tion of (simulated) patients who reach the pharmacodynamic 
targets formulated in point 2. This basic information is often 
missing or unclear in current modeling studies, although it 
is needed to support informed, evidence-based dosing rec-
ommendations for special populations, leading to improved 
clinical implementation of research findings.
Ideally, in the future, the mathematical backbone of pub-
lished pharmacokinetic models should be integrated in elec-
tronic health records to simplify finding the right dose for 
an individual patient. Bayesian forecasting software pack-
ages exist that provide evidence-based dosing advice for an 
individual patient, although integration in electronic health 
records remains in development [39, 40]. In coming years, 
implementation of these complex pharmacokinetic models 
and application of deep learning algorithms to continually 
improve model predictions will hopefully address the vari-
ability in special populations to ensure adequate drug expo-
sure for each individual patient.
5  Conclusion
In this pragmatic, retrospective study, we showed that recent, 
model-based dosing alterations for vancomycin, gentamicin, 
and tobramycin still result in substantial over- and underdos-
ing of critically ill neonates and children. Interestingly, sub-
optimal concentrations were most prevalent in term neonates 
and preterm neonates aged > 1 week. These findings indicate 
the importance of external, real-world validation of guide-
line changes. Future research should focus on addressing the 
large intra- and interpatient variability in special populations 
to improve exposure in this patient group and the implemen-
tation of evidence-based dosing in clinical practice.
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